PANX2 and nonpapillary renal cell carcinoma: Cy-PANX2 positivity showed a 3.713-fold (95% CI; 1.717–8.033) greater risk of death and a 3.432-fold (95% CI; 1.774–6.640) greater risk of relapse or death of CCRCC patients (Table 3).